{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T08:05:40Z","timestamp":1774771540081,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T00:00:00Z","timestamp":1476057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T00:00:00Z","timestamp":1476057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/bmt.2016.256","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T13:41:19Z","timestamp":1476106879000},"page":"1584-1587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Ruxolitinib treatment for GvHD in patients with myelofibrosis"],"prefix":"10.1038","volume":"51","author":[{"given":"Y","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,10]]},"reference":[{"key":"BFbmt2016256_CR1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V75.4.1011.1011","volume":"75","author":"E Holler","year":"1990","unstructured":"Holler E, Kolb HJ, Moller A, Kempeni J, Lisenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011\u20131016.","journal-title":"Blood"},{"key":"BFbmt2016256_CR2","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.V90.8.3204","volume":"90","author":"GR Hill","year":"1997","unstructured":"Hill GR, Crawford JM, Cooke KJ, Brinson YS, Pan L, Ferrara JLM . Total body irradiation and acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204\u20133213.","journal-title":"Blood"},{"key":"BFbmt2016256_CR3","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759","volume":"95","author":"GR Hill","year":"2000","unstructured":"Hill GR, Ferrara JL . The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754\u20132759.","journal-title":"Blood"},{"key":"BFbmt2016256_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nm0602-575","volume":"8","author":"T Teshima","year":"2002","unstructured":"Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575\u2013581.","journal-title":"Nat Med"},{"key":"BFbmt2016256_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbmt.2011.06.012","volume":"18","author":"A Xhaard","year":"2012","unstructured":"Xhaard A, Rocha V, Bueno B, de Latour RP, Lenglet J, Petropoulou A et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012; 18: 406\u2013413.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016256_CR6","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2002-03-0985","volume":"100","author":"JH Antin","year":"2002","unstructured":"Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100: 3479\u20133482.","journal-title":"Blood"},{"key":"BFbmt2016256_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2009-03-212290","volume":"114","author":"AM Alousi","year":"2009","unstructured":"Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511\u2013517.","journal-title":"Blood"},{"key":"BFbmt2016256_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A . The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311\u2013328.","journal-title":"Annu Rev Med"},{"key":"BFbmt2016256_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbmt.2015.10.001","volume":"22","author":"T Teshima","year":"2016","unstructured":"Teshima T, Reddy P, Zeiser R . Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant 2016; 22: 11\u201316.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016256_CR10","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T et al. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood 2014; 123: 3832\u20133842.","journal-title":"Blood"},{"key":"BFbmt2016256_CR11","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1182\/blood-2014-04-570325","volume":"123","author":"T Teshima","year":"2014","unstructured":"Teshima T . JAK inhibitors: a home run for GVHD patients? Blood 2014; 123: 3691\u20133693.","journal-title":"Blood"},{"key":"BFbmt2016256_CR12","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062\u20132068.","journal-title":"Leukemia"},{"key":"BFbmt2016256_CR13","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Brossart P, Wolf D . Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013; 122: 3843\u20133844.","journal-title":"Blood"},{"key":"BFbmt2016256_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A . Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86: 1188\u20131191.","journal-title":"Mayo Clin Proc"},{"key":"BFbmt2016256_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2013807.","journal-title":"N Engl J Med"},{"key":"BFbmt2016256_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787\u2013798.","journal-title":"N Engl J Med"},{"key":"BFbmt2016256_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","volume":"158","author":"FL Dignan","year":"2012","unstructured":"Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012; 158: 46\u201361.","journal-title":"Br J Haematol"},{"key":"BFbmt2016256_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","volume":"125","author":"ME Flowers","year":"2015","unstructured":"Flowers ME, Martin PJ . How we treat chronic graft-versus-host disease. Blood 2015; 125: 606\u2013615.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016256","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:27:43Z","timestamp":1648063663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,10]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFbmt2016256"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.256","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,10]]},"assertion":[{"value":"23 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TT has consultancy from Novartis Oncology. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}